The HBX-mediated interaction of SH2 domain-containing 5 (SH2D5) with transketolase (TKT) may activate STAT3 to increase HCC cell proliferation, and HBx was also reported to drive SH2D5 expression in HCC cells. Here, SH2D5 is linked to hepatocellular carcinoma.